2-Acetylpyridine thiosemicarbazones are potent iron chelators and antiproliferative agents: Redox activity, iron complexation and characterization of their antitumor activity

Journal of Medicinal Chemistry

Volumn 52, Issue 5, 2009, Pages 1459-1470

  Richardson, Des R ^a   Kalinowski, Danuta S ^a   Richardson, Vera ^a   Sharpe, Philip C ^b   Lovejoy, David B ^a   Islam, Mohammad ^b   Bernhardt, Paul V ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 NITROBENZOYL)PYRIDINE THIOSEMICARBAZONE; 2 ACETYLPYRIDINE 4 ALLYL 3 THIOSEMICARBAZONE; 2 ACETYLPYRIDINE 4 ETHYL 3 THIOSEMICARBAZONE; 2 ACETYLPYRIDINE 4 METHYL 3 THIOSEMICARBAZONE; 2 ACETYLPYRIDINE 4 PHENYL 3 THIOSEMICARBAZONE; 2 ACETYLPYRIDINE 4,4 DIMETHYL 3 THIOSEMICARBAZONE; 2 ACETYLPYRIDINE THIOSEMICARBAZONE; 2 BENZOYLPYRIDINE THIOSEMICARBAZONE; IMINE; IRON CHELATING AGENT; LIGAND; METHYL GROUP; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CHELATION; COMPLEX FORMATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; OXIDATION REDUCTION POTENTIAL; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; ASCORBIC ACID; CELL LINE, TUMOR; CELL PROLIFERATION; COORDINATION COMPLEXES; CRYSTALLOGRAPHY, X-RAY; DRUG SCREENING ASSAYS, ANTITUMOR; ELECTROCHEMICAL TECHNIQUES; HUMANS; IRON; IRON CHELATING AGENTS; OXIDATION-REDUCTION; PYRIDINES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; THIOSEMICARBAZONES; TRANSFERRIN;

EID: 64349093037     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801585u     Document Type: Article

References (91)

1. Kalinowski, D. S.; Richardson, D. R. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol. Rev. 2005, 57, 547-583.
2. Hershko, C. Control of disease by selective iron depletion: a novel therapeutic strategy utilizing iron chelators. Baillieres Clin. Haematol. 1994, 7, 965-1000.
3. Bernhardt, P. V. Coordination chemistry and biology of chelators for the treatment of iron overload disorders. J. Chem. Soc., Dalton Trans. 2007, 3214-3220.
4. Bernhardt, P. V.; Caldwell, L. M.; Chaston, T. B.; Chin, P.; Richardson, D. R. Cytotoxic iron chelators: characterization of the structure, solution chemistry and redox activity of ligands and iron complexes of the di-2-pyridyl ketone isonicotinoyl hydrazone (HPKIH) analogues. J. Biol. Inorg. Chem. 2003, 8, 866-880.
5. Richardson, D. R.; Sharpe, P. C.; Lovejoy, D. B.; Senaratne, D.; Kalinowski, D. S.; Islam, M.; Bernhardt, P. V. Dipyridyl thiosemi- carbazone chelators with potent and selective antitumor activity form iron complexes with redox activity. J. Med. Chem. 2006, 49, 6510-6521.
6. Kalinowski, D. S.; Sharpe, P. C.; Bernhardt, P. V.; Richardson, D. R. Design, synthesis, and characterization of new iron chelators with anti- proliferative activity: Structure-activity relationships of novel thio- hydrazone analogues. J. Med. Chem. 2007, 50, 6212-6225.
7. Kalinowski, D. S.; Yu, Y.; Sharpe, P. C.; Islam, M.; Liao, Y.-T.; Lovejoy, D. B.; Kumar, N.; Bernhardt, P. V.; Richardson, D. R. Design, synthesis, and characterization of novel iron chelators: Structure-activity relationships of the 2-benzoylpyridine thiosemi- carbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents. J. Med. Chem. 2007, 50, 3716-3729.
8. Buss, J. L.; Greene, B. T.; Turner, J.; Torti, F. M.; Torti, S. V. Iron chelators in cancer chemotherapy. Curr. Top. Med. Chem. 2004, 4, 1623-1635.
9. Torti, S. V.; Torti, F. M.; Whitman, S. P.; Brechbiel, M. W.; Park, G.; Planalp, R. P. Tumor cell cytotoxicity of a novel metal chelator. Blood 1998, 92, 1384-1389.
10. Rakba, N.; Loyer, P.; Gilot, D.; Delcros, J. G.; Glaise, D.; Baret, P.; Pierre, J. L.; Brissot, P.; Lescoat, G. Antiproliferative and apoptotic effects of O-Trensox, a new synthetic iron chelator, on differentiated human hepatoma cell lines. Carcinogenesis 2000, 21, 943-951.
11. Richardson, D. R. Molecular mechanisms of iron uptake by cells and the use of iron chelators for the treatment of cancer. Curr. Med. Chem. 2005, 12, 2711-2729.
12. Nyholm, S.; Mann, G. J.; Johansson, A. G.; Bergeron, R. J.; Graslund, A.; Thelander, L. Role of ribonucleotide reductase in inhibition of mammalian cell growth by potent iron chelators. J. Biol. Chem. 1993, 268, 26200-26205.
13. Cooper, C. E.; Lynagh, G. R.; Hoyes, K. P.; Hider, R. C.; Cammack, R.; Porter, J. B. The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase. J. Biol. Chem. 1996, 271, 20291-20299.
14. Kowol, C. R.; Berger, R.; Eichinger, R.; Roller, A.; Jakupec, M. A.; Schmidt, P. P.; Arion, V. B.; Keppler, B. K. Gallium(III) and iron(III) complexes of a-N-heterocyclic thiosemicarbazones: Synthesis, characterization, cytotoxicity, and interaction with ribonucleotide reductase. J. Med. Chem. 2007, 50, 1254-1265.
15. Richardson, D. R.; Tran, E. H.; Ponka, P. The potential ofiron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiprolif-erative agents. Blood 1995, 86, 4295-4306.
16. Nurtjahja-Tjendraputra, E.; Fu, D.; Phang, J.; Richardson, D. R. Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency mediated growth suppression. Blood 2007,109, 4045-4054.
17. Fu, D.; Richardson, D. R. Iron chelation and regulation of the cell cycle: Two mechanisms of post-transcriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion. Blood 2007, 110, 752-761.
18. Le, N. T. V.; Richardson, D. R. Iron chelators with high anti- proliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a novel link between iron metabolism and proliferation. Blood 2004, 104, 2967-2975.
19. Yuan, J.; Lovejoy, D. B.; Richardson, D. R. Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood 2004, 104, 1450-1458.
20. Whitnall, M.; Howard, J.; Ponka, P.; Richardson, D. R. A class of iron chelators with a wide spectrum of potent antitumor activity that overcome resistance to chemotherapeutics. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 14901-14906.
21. Agrawal, K. C.; Sartorelli, A. C. The chemistry and biological activity of a-(N)-heterocyclic carboxaldehyde thiosemicarbazones. Prog. Med. Chem. 1978, 15, 321-356.
22. West, D. X.; Liberta, A. E.; Padhye, S. B.; Chikate, R. C.; Sonawane, P. B.; Kumbhar, A. S.; Yerande, R. G. Thiosemicarbazone complexes of copper(II): structural and biological studies. Coord. Chem. Rev. 1993, 123, 49-71.
23. Liu, M.-C.; Lin, T.-S.; Sartorelli, A. C. Chemical and biological properties of cytotoxic a-(N)-heterocyclic carboxaldehyde thiosemi- carbazones. Prog. Med. Chem. 1995, 32, 1-35.
24. Casas, J. S.; Garcia-Tasende, M. S.; Sordo, J. Main group metal complexes of semicarbazones and thiosemicarbazones. A structural review. Coord. Chem. Rev. 2000, 209, 197-261.
25. Li, J.; Zheng, L.-M.; King, I.; Doyle, T. W.; Chen, S.-H. Syntheses and antitumor activities of ribonucleotide reductase inhibitors: 3-amino- pyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) and its phosphate bearing water-soluble prodrugs. Front. Biotechnol. Pharm. 2000, 1, 314-335.
26. Quiroga, A. G.; Navarro Ranninger, C. Contribution to the SAR field of metalated and coordination complexes: studies of the palladium and platinum derivatives with selected thiosemicarbazones as antitu- moral drugs. Coord. Chem. Rev. 2004, 248, 119-133.
27. Greenbaum, D. C.; Mackey, Z.; Hansell, E.; Doyle, P.; Gut, J.; Caffrey, C. R.; Lehrman, J.; Rosenthal, P. J.; McKerrow, J. H.; Chibale, K. Synthesis and structure-activity relationships of parasiticidal thi- osemicarbazone cysteine protease inhibitors against Plasmodium falciparum, Trypanosoma brucei, and Trypanosoma cruzi. J. Med. Chem. 2004, 47, 3212-3219.
28. Walcourt, A.; Loyevsky, M.; Lovejoy, D. B.; Gordeuk, V. R.; Richardson, D. R. Novel aroylhydrazone and thiosemicarbazone iron chelators with antimalarial activity against chloroquine-resistant and -sensitive parasites. Int. J. Biochem. Cell Biol. 2004, 36, 401-407.
29. Biot, C.; Pradines, B.; Sergeant, M.-H.; Gut, J.; Rosenthal, P. J.; Chibale, K. Design, synthesis, and antimalarial activity of structural chimeras of thiosemicarbazone and ferroquine analogs. Bioorg. Med. Chem. Lett. 2007, 17, 6434-6438.
30. Kovala-Demertzi, D.; Demertzis, M. A.; Miller, J. R.; Papadopoulou, C.; Dodorou, C.; Filousis, G. Platinum(II) complexes with 2-acetylpy- ridine thiosemicarbazone. Synthesis, crystal structure, spectral properties, antimicrobial and antitumour activity. J. Inorg. Biochem. 2001, 86, 555-563.
31. Kasuga, N. C.; Sekino, K.; Ishikawa, M.; Honda, A.; Yokoyama, M.; Nakano, S.; Shimada, N.; Koumo, C.; Nomiya, K. Synthesis, structural characterization and antimicrobial activities of 12 zinc(II) complexes with four thiosemicarbazone and two semicarbazone ligands. J. Inorg. Biochem. 2003, 96, 298-310.
32. Kasuga, N. C.; Onodera, K.; Nakano, S.; Hayashi, K.; Nomiya, K. Syntheses, crystal structures and antimicrobial activities of 6-coordinate antimony(III) complexes with tridentate 2-acetylpyridine thiosemi- carbazone, bis(thiosemicarbazone) and semicarbazone ligands. J. Inorg. Biochem. 2006, 100, 1176-1186.
33. de Aquino, T. M.; Liesen, A. P.; da Silva, R. E. A.; Lima, V. T.; Carvalho, C. S.; de Faria, A. R.; de Araujo, J. M.; de Lima, J. G.; Alves, A. J.; de Melo, E. J. T.; Goes, A. J. S. Synthesis, anti- Toxoplasma gondii and antimicrobial activities of benzaldehyde 4-phenyl-3-thiosemicarbazones and 2-[(phenylmethylene)hydrazono]- 4-oxo-3-phenyl-5-thiazolidineacetic acids. Bioorg. Med. Chem. 2008,16, 446-456.
34. Kannan, S.; Sivagamasundari, M.; Ramesh, R.; Liu, Y. Ruthenium(II) carbonyl complexes of dehydroacetic acid thiosemicarbazone: synthesis, structure, light emission and biological activity. J. Organomet. Chem. 2008, 693, 2251-2257.
35. Mendes, I. C.; Moreira, J. P.; Ardisson, J. D.; Gouvea dos Santos, R.; da Silva, P. R. O.; Garcia, I.; Castineiras, A.; Beraldo, H. Organotin(IV) complexes of 2-pyridineformamide-derived thiosemicarbazones: antimicrobial and cytotoxic effects. Eur. J. Med. Chem. 2008, 43, 1454-1461.
36. Liu, M.-C.; Lin, T.-S.; Penketh, P.; Sartorelli, A. C. Synthesis and antitumor activity of 4- and 5-substituted derivatives of isoquinoline- 1-carboxaldehyde thiosemicarbazone. J. Med. Chem. 1995, 38, 4234-4243.
37. Baldini, M.; Belicchi-Ferrari, M.; Bisceglie, F.; Dall'Aglio, P. P.; Pelosi, G.; Pinelli, S.; Tarasconi, P. Copper(II) complexes with substituted thiosemicarbazones of a-ketoglutaric acid: synthesis, X-ray structures, DNA binding studies, and nuclease and biological activity. Inorg. Chem. 2004, 43, 7170-7179.
38. Padhye, S.; Afrasiabi, Z.; Sinn, E.; Fok, J.; Mehta, K.; Rath, N.
39. Antitumor metallothiosemicarbazonates: structure and antitumor activity of palladium complex of phenanthrenequinone thiosemicarbazone. Inorg. Chem. 2005, 44, 1154-1156.
40. Perez-Rebolledo, A.; Ayala, J. D.; de Lima, G. M.; Marchini, N.; Bombieri, G.; Zani, C. L.; Souza-Fagundes, E. M.; Beraldo, H. Structural studies and cytotoxic activity of N(4)-phenyl-2-benzoylpy- ridine thiosemicarbazone Sn(IV) complexes. Eur. J. Med. Chem. 2005, 40, 467-472.
41. Adsule, S.; Barve, V.; Chen, D.; Ahmed, F.; Dou, Q. P.; Padhye, S.; Sarkar, F. H. Novel Schiff base copper complexes of quinoline-2 carboxaldehyde as proteasome inhibitors in human prostate cancer cells. J. Med. Chem. 2006, 49, 7242-7246.
42. Barker, C. A.; Burgan, W. E.; Carter, D. J.; Cerna, D.; Gius, D.; Hollingshead, M. G.; Camphausen, K.; Tofilon, P. J. In vitro and in vivo radiosensitization induced by the ribonucleotide reductase inhibitor triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone). Clin. Cancer Res. 2006, 12, 2912-2918.
43. bHu, W.-X.; Zhou, W.; Xia, C.-N.; Wen, X. Synthesis and anticancer activity of thiosemicarbazones. Bioorg. Med. Chem. Lett. 2006, 16, 2213-2218.
44. Kovala-Demertzi, D.; Yadav, P. N.; Wiecek, J.; Skoulika, S.; Vara- dinova, T.; Demertzis, M. A. Zinc(II) complexes derived from pyridine-2-carbaldehyde thiosemicarbazone and (1E)-1-pyridin-2- ylethan-1-one thiosemicarbazone. Synthesis, crystal structures and antiproliferative activity of zinc(II) complexes. J. Inorg. Biochem. 2006, 100, 1558-1567.
45. Bisceglie, F.; Baldini, M.; Belicchi-Ferrari, M.; Buluggiu, E.; Careri, M.; Pelosi, G.; Pinelli, S.; Tarasconi, P. Metal complexes of retinoid derivatives with antiproliferative activity: synthesis, characterization and DNA interaction studies. Eur. J. Med. Chem. 2007, 42, 627-634.
46. Grguric-Sipka, S.; Kowol, C. R.; Valiahdi, S.-M.; Eichinger, R.; Jakupec, M. A.; Roller, A.; Shova, S.; Arion, V. B.; Keppler, B. K. Ruthenium(II) complexes of thiosemicarbazones: the first water-soluble complex with pH dependent antiproliferative activity. Eur. J. Inorg. Chem. 2007, 2870-2878.
47. Matesanz, A. I.; Souza, P. Novel cyclopalladated and coordination palladium and platinum complexes derived from a-diphenyl ethanedi- one bis(thiosemicarbazones): Structural studies and cytotoxic activity against human A2780 and A2780cisR carcinoma cell lines. J. Inorg. Biochem. 2007, 101, 1354-1361.
48. Dilovic, I.; Rubcic, M.; Vrdoljak, V.; Pavelic, S. K.; Kralj, M.; Piantanida, I.; Cindric, M. Novel thiosemicarbazone derivatives as potential antitumor agents: synthesis, physicochemical and structural properties, DNA interactions and antiproliferative activity. Bioorg. Med. Chem. 2008, 16, 5189-5198.
49. Liu, M. C.; Lin, T. C.; Sartorelli, A. C. Synthesis and antitumor activity of amino derivatives of pyridine-2-carboxaldehyde thiosemicarbazone. J. Med. Chem. 1992, 35, 3672-3677.
50. Cory, J. G.; Cory, A. H.; Rappa, G.; Lorico, A.; Liu, M.-C.; Lin, T.- S.; Sartorelli, A. C. Inhibitors of ribonucleotide reductase: comparative effects of amino- and hydroxy-substituted pyridine-2-carboxaldehyde thiosemicarbazones. Biochem. Pharmacol. 1994, 48, 335-344.
51. Feun, L.; Modiano, M.; Lee, K.; Mao, J.; Marini, A.; Savaraj, N.; Plezia, P.; Almassian, B.; Colacino, E.; Fischer, J.; MacDonald, S. Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxal- dehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule. Cancer Chemother. Pharmacol. 2002, 50, 223-229.
52. Wadler, S.; Makower, D.; Clairmont, C.; Lambert, P.; Fehn, K.; Sznol, M. Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96 h intravenous continuous infusion. J. Clin. Oncol. 2004, 22, 1553-1563.
53. Mackenzie, M. J.; Saltman, D.; Hirte, H.; Low, J.; Johnson, C.; Pond, G.; Moore, M. J. A Phase II study of 3-aminopyridine-2-carboxalde- hyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret Hospital Phase II consortium. Invest. New Drugs 2007, 25, 553-558.
54. Attia, S.; Kolesar, J.; Mahoney, M. R.; Pitot, H. C.; Laheru, D.; Heun, J.; Huang, W.; Eickhoff, J.; Erlichman, C.; Holen, K. D. A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemi- carbazone (3-AP) for advanced adenocarcinoma of the pancreas. Invest. New Drugs 2008, 26, 369-379.
55. Ma, B.; Goh, B. C.; Tan, E. H.; Lam, K. C.; Soo, R.; Leong, S. S.; Wang, L. Z.; Mo, F.; Chan, A. T. C.; Zee, B.; Mok, T. A. multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mono- nuclear cells. Invest. New Drugs 2008, 26, 169-173.
56. Finch, R. A.; Liu, M.; Grill, S. P.; Rose, W. C.; Loomis, R.; Vasquez, K. M.; Cheng, Y.; Sartorelli, A. C. Triapine (3-aminopyridine-2- carboxaldehyde-thiosemicarbazone): a potent inhibitor of ribonucle- otide reductase activity with broad spectrum antitumor activity. Biochem. Pharmacol. 2000, 59, 983-991.
57. Kumbhar, A.; Sonawane, P.; Padhye, S.; West, D. X.; Butcher, R. J. Structure of antitumor agents 2-acetylpyridinethiosemicarbazone hemi- hydrate and 2-acetylpyridinethiosemicarbazone hydrochloride. J. Chem. Crystallogr. 1997, 27, 533-539.
58. Bermejo, E.; Carballo, R.; Castineiras, A.; Dominguez, R.; Liberta, A. E.; Maichle-Mossmer, C.; Salberg, M. M.; West, D. X. Synthesis, structural characteristics, and biological activities of complexes of Zn(II), Cd(II), Hg(II), Pd(II), and Pt(II) with 2-acetylpyridine-4-methylthiosemicarbazone. Eur. J. Inorg. Chem. 1999, 96, 5-973.
59. West, D. X.; Bain, G. A.; Butcher, R. J.; Valdes-Martinex, J.; Toscano, R. A.; Hernandez-Ortega, S.; Jasinsky, J. P.; Li, Y.; Pozdniakiv, R. Y. Structural studies of three isomeric forms of heterocyclic N(4)- substituted thiosemicarbazones and two nickel(II) complexes. Polyhedron 1996, 15, 665-674.
60. Bermejo, E.; Castineiras, A.; Dominguez, R.; Carballo, R.; Maichle- Mossmer, C.; Strahle, J.; West, D. X. Preparation, structural charac- terization, and antifungal activities of complexes of group 12 metals with 2-acetylpyridine- and 2-acetylpyridine-N-oxide-4N-phenylthi- osemicarbazones. Z. Anorg. Allg. Chem. 1999, 625, 961-968.
61. Kowol, C. R.; Eichinger, R.; Jakupec, M. A.; Galanski, M.; Arion, V. B.; Keppler, B. K. Effect of metal ion complexation and chalcogen donor identity on the antiproliferative activity of 2-acetylpyridine N,N- dimethyl(chalcogen)semicarbazones. J. Inorg. Biochem. 2007, 101, 1946-1957.
62. West, D. X.; Scovill, J. P.; Silverton, J. V.; Bavoso, A. Nickel(II) complexes of a thiosemicarbazone prepared from 2-acetylpyridine. Transition Met. Chem. 1986, 11, 123-131.
63. West, D. X.; Billeh, I. S.; Bain, G. A.; Valdes-Martinez, J.; Ebert, K. H.; Hernandez-Ortega, S. Metal complexes of 2-acetylpyridine N(4)- dihexyl- and N(4)-dicyclohexylthiosemicarbazones. Transition Met. Chem. 1996, 21, 573-582.
64. Nomiya, K.; Sekino, K.; Ishikawa, M.; Honda, A.; Yokoyama, M.; Chikaraishi Kasuga, N.; Yokoyama, H.; Nakano, S.; Onodera, K. Syntheses, crystal structures and antimicrobial activities of monomeric 8-coordinate, and dimeric and monomeric 7-coordinate bismuth(III) complexes with tridentate and pentadentate thiosemicarbazones and pentadentate semicarbazone ligands. J. Inorg. Biochem. 2004, 98, 601-615.
65. Usman, A.; Razak, I. A.; Chantrapromma, S.; Fun, H. K.; Philip, V.; Sreekanth, A.; Prathapachandra Kurup, M. R. Di-2-pyridyl ketone N4,N4-(butane-1,4-diyl)thiosemicarbazone. Acta Crystallogr., Sect. C: Cryst. Struct. Commun. 2002, C58, o652-o654.
66. 2O and the free ligand. Polyhedron 2004, 23, 969-978.
67. Ketcham, K. A.; Swearingen, J. K.; Castineiras, A.; Garcia, I.; Bermejo, E.; West, D. X. Iron(III), cobalt(II, III), copper(II) and zinc(II) complexes of 2-pyridineformamide 3-piperidylthiosemicarbazone. Polyhedron 2001, 20, 3265-3273.
68. Bermejo, E.; Castifieiras, A.; Fostiak, L. M.; Garcia, I.; Llamas-Saiz, A. L.; Swearingen, J. K.; West, D. X. Synthesis; characterization and molecular structure of 2-pyridylformamide N(4)-dimethylthiosemi- carbazone and some five-coordinated zinc(II) and cadmium(II) complexes. Z. Naturforsch., B: Chem. Sci. 2001, 56, 1297-1305.
69. Richardson, D. R.; Bernhardt, P. V. Crystal and molecular structure of 2-hydroxy-1-naphthaldehyde isonicotinoyl hydrazone (NIH) and its iron(III) complex: an iron chelator with antitumor activity. J. Biol. Inorg. Chem. 1999, 4, 266-273.
70. Murphy, T. B.; Johnson, D. K.; Rose, N. J.; Aruffo, A.; Schomaker, V. Structural studies of iron(III) complexes of the new iron-binding drug, pyridoxal isonicotinoyl hydrazone. Inorg. Chim. Acta 1982, 66, L67-L68.
71. Avramovici-Grisaru, S.; Sarel, S.; Cohen, S.; Bauminger, R. E. The synthesis, crystal and molecular-structure, and oxidation-state of iron complex from pyridoxal isonicotinoyl hydrazone and ferrous sulfate. Israel J. Chem. 1985, 25, 288-292.
72. Bernhardt, P. V.; Wilson, G. J.; Sharpe, P. C.; Kalinowski, D. S.; Richardson, D. R. Tuning the antiproliferative activity of biologically active iron chelators: characterization of the coordination chemistry and biological efficacy of 2-acetylpyridine and 2-benzoylpyridine hydrazone ligands. J. Biol. Inorg. Chem. 2008, 13, 107-119.
73. Dunford, H. B. Oxidations of iron(II)/(III) by hydrogen peroxide: from aquo to enzyme. Coord. Chem. Rev. 2002, 233-234, 311-318.
74. Chaston, T. B.; Richardson, D. R. Redox chemistry and DNA interactions of the 2-pyridyl-carboxaldehyde isonicotinoyl hydrazone class of iron chelators: implications for toxicity in the treatment of iron overload disease. J. Biol. Inorg. Chem. 2003, 8, 427-438.
75. Chaston, T.; Lovejoy, D.; Watts, R. N.; Richardson, D. R. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of Triapine compared to Desferrioxamine and the potent PIH analogue 311. Clin. Cancer Res. 2003, 9, 402-414.
76. Ledru, S.; Boujtita, M. Electrocatalytic oxidation of ascorbate by heme- FeIII/heme-FeII redox couple of the HRP and its effect on the electrochemical behavior of an L-lactate biosensor. Bioelectrochemistry 2004, 64, 71-78.
77. Ponka, P.; Schulman, H. M. Acquisition of iron from transferrin regulates reticulocyte heme synthesis. J. Biol. Chem. 1985, 260, 14717-14721.
78. (77)Ponka, P.; Schulman, H. M.; Wilczynska, A. Ferric pyridoxal isonicotinoyl hydrazone can provide iron for heme synthesis in reticulocytes. Biochim. Biophys. Acta 1982, 718, 151-156.
79. Bernhardt, P. V.; Mattsson, J.; Richardson, D. R. Complexes of cytotoxic chelators from the dipyridyl ketone isonicotinoyl hydrazone (HPKIH) analogues. Inorg. Chem. 2006, 45, 752-760.
80. Bernhardt, P. V.; Sharpe, P. C.; Islam, M.; Lovejoy, D. B.; Kalinowski, D. S.; Richardson, D. R. Iron chelators of the dipyridylketone thiosemicarbazone class: precomplexation and transmetalation effects
81. on anticancer activity. J. Med. Chem. 2009, 52, 407-415.
82. Richardson, D. R.; Ponka, P. The iron metabolism of the human neuroblastoma cell. Lack of relationship between the efficacy of iron chelation and the inhibition ofDNA synthesis. J. Lab. Clin. Med. 1994, 124, 660-671.
83. Richardson, D. R.; Milnes, K. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II. The mechanism of action of ligands derived from salicy- laldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde ben- zoyl hydrazone. Blood 1997, 89, 3025-3038.
84. Darnell, G.; Richardson, D. R. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: The effect of the ligands on molecular targets involved in proliferation. Blood 1999, 94, 781-792.
85. Baker, E.; Richardson, D. R.; Gross, S.; Ponka, P. Evaluation of the iron chelation potential of hydrazones of pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde using the hepatocyte in culture. Hepatology 1992, 15, 492-501.
86. Kontoghiorghes, G. J.; Evans, R. W. Site specificity of iron removal from transferrin by alpha-ketohydroxypyridine chelators. FEBS Lett. 1985, 189, 141-144.
87. Bernhardt, P. V.; Chin, P.; Sharpe, P. C.; Wang, J.-Y. C.; Richardson, D. R. Novel diaroylhydrazine ligands as iron chelators: coordination chemistry and biological activity. J. Biol. Inorg. Chem. 2005, 10, 761-777.
88. Sheldrick, G. M. SHELX97. Programs for Crystal Structure Analysis, release 97-2; University of Gottingen, Gottingen, Germany, 1998.
89. Farrugia, L. J. ORTEP-3 for windows-a version of ORTEP-III with a graphical user interface (GUI). J. Appl. Crystallogr. 1997, 30, 565.
90. Richardson, D. R.; Baker, E. The uptake of iron and transferrin by the human malignant melanoma cell. Biochim. Biophys. Acta 1990, 1053, 1-12.
91. Richardson, D.; Baker, E. Two mechanisms of iron uptake from transferrin by melanoma cells. The effect of desferrioxamine and ferric ammonium citrate. J. Biol. Chem. 1992, 267, 13972-13979.